Yuto Watanabe, Tomohide Tsukahara, Kenji Murata, Shuto Hamada, Terufumi Kubo, Takayuki Kanaseki, Yoshihiko Hirohashi, Makoto Emori, Atsushi Teramoto, Munehide Nakatsugawa, Toshihiko Yamashita and Toshihiko Torigoe
British Journal of Cancer, 16 December 2022
Scientists use Axion’s Maestro Z live-cell analysis platform to explore the efficacy of B10 CAR T cells against renal cell carcinoma and osteosarcoma.
CAR T cell therapies have shown limited efficacy against solid tumors and research into novel targets is ongoing. In this study, scientists generate a B10 CAR T cell population which is reactive to the cancer stem cell/cancer initiating cell antigen DNAJB8 in the context of HLA-A*24:02 molecules and investigate its impact on renal cell carcinoma (RCC) and osteosarcoma. Using Axion’s noninvasive Maestro Z live-cell analyzer, the team found that the B10 CAR Ts effectively targeted DNAJB8/ HLA-A*24:02-expressing osteosarcoma cell lines in vitro. Taken together with other findings in the study, the authors conclude that “B10 CAR T cells targeting the cancer stem cell antigen DNAJB8 showed strong anti-tumour activities against RCC and osteosarcoma cells in vitro and rejected xenografted tumours in vivo,” suggesting that B10 CAR T cells may be a promising therapeutic approach for some cancers.